Academic Journal

Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy

التفاصيل البيبلوغرافية
العنوان: Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy
المؤلفون: Borghi L., Rosti G., Maggi A., Breccia M., Di Bona E., Iurlo A., La Barba G., Sportoletti P., Albano F., Galimberti S., Rivellini F., Cambrin G. R., Capodanno I., Cuneo A., Bonifacio M., Sica S., Arcaini L., Capochiani E., Minotto C., Ciceri F., Crugnola M., Di Caprio L., Supekar S., Elena C., Baccarani M., Vegni E.
المساهمون: Borghi, L., Rosti, G., Maggi, A., Breccia, M., Di Bona, E., Iurlo, A., La Barba, G., Sportoletti, P., Albano, F., Galimberti, S., Rivellini, F., Cambrin, G. R., Capodanno, I., Cuneo, A., Bonifacio, M., Sica, S., Arcaini, L., Capochiani, E., Minotto, C., Ciceri, F., Crugnola, M., Di Caprio, L., Supekar, S., Elena, C., Baccarani, M., Vegni, E.
سنة النشر: 2021
المجموعة: Università degli Studi di Ferrara: CINECA IRIS
مصطلحات موضوعية: Chronic myeloid leukemia, emotional experience, ENESTPath, mixed method, nilotinib, psychological distre, quality of life, study protocol
الوصف: Achievement of deep molecular response following treatment with a tyrosine kinase inhibitor (TKI) allows for treatment-free remission (TFR) in many patients with chronic myeloid leukemia (CML). Successful TFR is defined as the achievement of a sustained molecular response after cessation of ongoing TKI therapy. The phase 3 ENESTPath study was designed to determine the required optimal duration of consolidation treatment with the second-generation TKI, nilotinib 300 mg twice-daily, to remain in successful TFR without relapse after entering TFR for 12 months. The purpose of this Italian ‘patient’s voice CML’ substudy was to evaluate patients’ psycho-emotional characteristics and quality of life through their experiences of stopping treatment with nilotinib and entering TFR. The purpose of the present contribution is to early present the study protocol of an ongoing study to the scientific community, in order to describe the study rationale and to extensively present the study methodology. Patients aged ≥18 years with a confirmed diagnosis of Philadelphia chromosome positive BCR-ABL1+ CML in chronic phase and treated with front-line imatinib for a minimum of 24 months from the enrollment were eligible. Patients consenting to participate the substudy will have quality of life questionnaires and in-depth qualitative interviews conducted. The substudy will include both qualitative and quantitative design aspects to evaluate the psychological outcomes as assessed via patients’ emotional experience during and after stopping nilotinib therapy. Randomization is hypothesized to be a timepoint of higher psychological alert or distress when compared to consolidation and additionally any improvement in health-related quality of life (HRQoL) due to nilotinib treatment is expected across the timepoints (from consolidation, to randomization, and TFR). An association is also expected between dysfunctional coping strategies, such as detachments and certain personality traits, and psychological distress and HRQoL impairments. ...
نوع الوثيقة: article in journal/newspaper
وصف الملف: STAMPA
اللغة: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/34123791; info:eu-repo/semantics/altIdentifier/wos/WOS:000659232900001; volume:11; firstpage:638689-1; lastpage:638689-9; numberofpages:9; journal:FRONTIERS IN ONCOLOGY; https://hdl.handle.net/11392/2461774; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85107840565; https://www.frontiersin.org/articles/10.3389/fonc.2021.638689/full
DOI: 10.3389/fonc.2021.638689
DOI: 10.3389/fonc.2021.638689/full
الاتاحة: https://hdl.handle.net/11392/2461774
https://doi.org/10.3389/fonc.2021.638689
https://www.frontiersin.org/articles/10.3389/fonc.2021.638689/full
Rights: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.5C0381A7
قاعدة البيانات: BASE
الوصف
DOI:10.3389/fonc.2021.638689